Fatty Liver Disease Collaborative Research in China (FLDCR)
A Multi-center, Prospective Cohort Study on the Natural History of Fatty Liver Disease in China
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jiangao Fan, MD
- Email: fattyliver2004@126.com
Study Contact Backup
- Name: Chao Sun, MD
- Email: csun7682@163.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Xinhua hospital
-
Contact:
- Jiangao Fan, MD
- Email: fattyliver2004@126.com
-
-
Fujian
-
Zhangzhou, Fujian, China
- Not yet recruiting
- Zhangzhou Zhengxing Hospital
-
Contact:
- Ruidan Zheng, MD
-
Principal Investigator:
- Ruidan Zheng, MD
-
-
Shandong
-
Ji'nan, Shandong, China
- Not yet recruiting
- Shandong Provincial Hospital
-
Principal Investigator:
- Wanhua Ren, MD
-
-
Tianjin
-
Tianjin, Tianjin, China
- Not yet recruiting
- Tianjin Second People's Hospital
-
Contact:
- Yuqiang Mi, MD
-
Principal Investigator:
- Yuqiang Mi, MD
-
-
Xinjiang
-
Urumqi, Xinjiang, China
- Not yet recruiting
- The First Affiliated Hospital of Xinjiang Medical University
-
Contact:
- Fangping He, MD
-
Principal Investigator:
- Fangping He, MD
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Not yet recruiting
- The Affiliated Hospital of Hangzhou Normal University
-
Principal Investigator:
- Junping Shi, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinically diagnosed fatty liver disease, confirmed by liver biopsy.
- Specific biopsy requirements: qualified biopsy specimen within 6 months, >5% hepatocytes show macrovesicular steatosis under HE staining and X10 microscope.
- Only patients with NAFLD or ALD are eligible for the 5-year follow-up cohort study.
- Willing to participate in the long-term follow-up and cooperative.
- Able to provide informed consent file.
Exclusion Criteria:
- Unable to provide informed consent.
Patients are eligible for baseline cross-sectional analysis but not eligible for the cohort section, if having any of the following condition:
- Any end-stage liver disease.
- Any malignant tumor.
- Any infection of hepatitis virus or HIV.
- Any congenital liver disease such as Wilson disease.
- Any other serious disease of projected survival < 5 years.
- Combined NAFLD and ALD.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
liver cirrhosis
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
liver cancer
Time Frame: 5 years
|
5 years
|
|
liver failure
Time Frame: 5 years
|
5 years
|
|
type 2 diabetes
Time Frame: 5 years
|
5 years
|
|
cardiovascular and cerebrovascular events
Time Frame: 5 years
|
5 years
|
|
death
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jiangao Fan, MD, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FLD2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.